Am Law 100 firm Polsinelli recently advised client API Innovation Center (APIIC) on its successful application to obtain funding by the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to lead the development and domestic production of three critical active pharmaceutical ingredients (APIs) used in the treatment of asthma, diabetes and anxiety disorders. APIIC is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, dedicated to driving health security and economic growth for the nation and its citizens through U.S.-based production of critical medicines. This is the Biden-Harris Administration’s first award under the Defense Production Act Title III to onshore manufacturing of active pharmaceutical ingredients for essential medicines.

IBMSC will provide $14 million in funding and APIIC will invest an additional $2.4 million into the development of these critical APIs. This funding marks a significant step forward in securing the U.S. pharmaceutical supply chain and addressing national health security risks.

More information on the news can be found here.

Shareholders Arindam Kar and James W. Kim advised the client in this matter along with Associates Cate Baskin and Elizabeth Snyder.